Novo Nordisk's stock has recently plummeted, with some reports citing poor trial results for a new obesity drug as a factor. The company's stock has fallen to its lowest point in nearly five years, down significantly from its high. The decline may be related to a rival company, Eli Lilly, outperforming Novo Nordisk in a study, although the full reasons for the stock's drop are not entirely clear.